Page last updated: 2024-12-05

methacetin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

methacetin: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

methacetin : A member of the class of acetamides that is paracetamol in which the hydrogen of phenolic hydroxy group has been replaced by a methyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5827
CHEMBL ID3183230
CHEBI ID139354
SCHEMBL ID171415
SCHEMBL ID12015254
SCHEMBL ID17955676
MeSH IDM0108729

Synonyms (70)

Synonym
HMS1783M19
EN300-15545
4-acetamidoanisole
p-acetaniside
n-acetyl-p-methoxyaniline
acetyl-p-anisidine
51-66-1
nsc-4687
p-methoxyacetanilide
4'-methoxyacetanilide
nsc4687
aceto-p-anisidide
acetanilide, 4'-methoxy-
acetamide, n-(4-methoxyphenyl)-
metacetin
wln: 1vmr do1
p-acetanisidine
p-acetanisidide
methacetin
4-methoxyacetanilide
n-acetyl-p-anisidine
nsc 4687
brn 0387887
einecs 200-114-2
ai3-00798
AE-641/00642037
n-(4-methoxyphenyl)acetamide ,
inchi=1/c9h11no2/c1-7(11)10-8-3-5-9(12-2)6-4-8/h3-6h,1-2h3,(h,10,11
STK045687
4-(acetylamino)anisole
CHEBI:139354
n-(4-methoxyphenyl)acetic acid amide
A0019
AKOS000121469
A7614
NCGC00248932-01
unii-13e468tfhp
13e468tfhp ,
NCGC00258683-01
cas-51-66-1
tox21_201131
dtxsid6026325 ,
dtxcid806325
n-(4-methoxyphenyl)-acetamide
F1962-0209
FT-0671108
FT-0618905
acetanisidide, p-
p-acetanisidine [mi]
SCHEMBL171415
4-acetaminoanisole
n-(4-methoxy-phenyl)-acetamide
p-acetamidoanisole
SCHEMBL12015254
aceto-p-anisidine
n-(p-methoxyphenyl)acetamide
CHEMBL3183230
SR-01000395318-1
sr-01000395318
SCHEMBL17955676
mfcd00014963
SY078829
DS-15877
T9V ,
AMY824
BB 0323203
Q27251512
n-(4-methoxyphenyl)ethanamide
CS-0072050
Z28138902

Research Excerpts

Overview

Methacetin is thought to be a good substrate for the evaluation of different cytochrome P450 enzymatic systems of liver microsomes because of its rapid metabolism and lack of toxicity in small doses.

ExcerptReferenceRelevance
"Methacetin is thought to be a good substrate for the evaluation of different cytochrome P450 enzymatic systems of liver microsomes because of its rapid metabolism and lack of toxicity in small doses. "( Utility of a 13C-methacetin breath test in evaluating hepatic injury in rats.
Aeed, H; Avni, Y; Ilan, Y; Shahmurov, M; Shalev, T; Shirin, H; Sorin, V; Stavinski, S, 2008
)
2.13
"Methacetin is a test drug assessing a two-step pathway of biotransformation including monooxygenation and conjugation."( Hepatic biotransformation capacity in low-birth-weight infants as measured with the [15N]methacetin urine test: influences of gestational age, postnatal age, and intrauterine growth retardation.
Boehm, G; Krumbiegel, P; Teichmann, B, 1995
)
1.23

Compound-Compound Interactions

ExcerptReferenceRelevance
"The results of investigations had showed the high efficiency of the combination of atorvastatin with telmisartan in patients with arterial hypertension combined with obesity and NAFLD."( Combined effect of appointment telmisartan and atorvastatin on hemodynamic indicators and the indicators of lipid profile in patients with arterial hypertension combined with obesity and steatohepatitis.
Bochar, OM, 2014
)
0.4

Bioavailability

ExcerptReferenceRelevance
"Methacetin is well absorbed and exclusively metabolized in the liver."( Utility of a 13C-methacetin breath test in evaluating hepatic injury in rats.
Aeed, H; Avni, Y; Ilan, Y; Shahmurov, M; Shalev, T; Shirin, H; Sorin, V; Stavinski, S, 2008
)
2.13

Dosage Studied

The LiMAx test, which is based on intravenous injection of (13)C-methacetin at a dosage of 2 mg/kg body weight was performed in eighty-six healthy subjects to determine a reference range. The aim of this study was to check whether currently used dosage regimens of [(13]C]meth acetin provide concordant results in subjects with an atypical body constitution.

ExcerptRelevanceReference
" Although these results are not generally applicable, they contribute to a better interpretation of the [15N]methacetin liver function test--for instance when estimating effects due to environmental exposure or accurately calculating age-related drug dosage for neonates."( Maturation of hepatosomal mono-oxygenation and glucuronidation activities in pre- and full-term infants as studied using the [15N]methacetin urine test.
Boehm, G; Braun, W; Domke, S; Krumbiegel, P; Mörseburg, B, 1997
)
0.71
" The aim of this study was to check whether currently used dosage regimens of [(13)C]methacetin provide concordant [(13)C]MBT results in subjects with an atypical body constitution."( Comparison of two dosage regimens of the substrate for the [13C]methacetin breath test.
Budniok, M; Błońska-Fajfrowska, B; Jonderko, K; Kasicka-Jonderko, A; Krusiec-Świdergo, B, 2013
)
0.85
"The LiMAx test, which is based on intravenous injection of (13)C-methacetin at a dosage of 2 mg/kg body weight was performed in eighty-six healthy subjects to determine a reference range."( Reliable assessment of liver function using LiMAx.
Bednarsch, J; Jara, M; Jung, T; Lock, JF; Malinowski, M; Schulz, A; Seehofer, D; Stockmann, M; Valle, E, 2015
)
0.65
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
acetamidesCompounds with the general formula RNHC(=O)CH3.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency25.12210.003041.611522,387.1992AID1159552; AID1159555
estrogen nuclear receptor alphaHomo sapiens (human)Potency39.55350.000229.305416,493.5996AID743079
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (113)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (11.50)18.7374
1990's15 (13.27)18.2507
2000's31 (27.43)29.6817
2010's44 (38.94)24.3611
2020's10 (8.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.56 (24.57)
Research Supply Index4.88 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index35.70 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials10 (8.26%)5.53%
Reviews7 (5.79%)6.00%
Case Studies3 (2.48%)4.05%
Observational1 (0.83%)0.25%
Other100 (82.64%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]